超声肾脏去神经对难治性动脉高血压患者办公室血压的有效性和安全性:系统回顾与元分析》。

IF 3.1 Q2 PERIPHERAL VASCULAR DISEASE
Jose Guilherme Maia, Francinny Alves Kelly, Ocilio Ribeiro Gonçalves, Francisco Cezar Aquino de Moraes, Marcio Gonçalves de Sousa, Fernanda Marciano Consolim-Colombo
{"title":"超声肾脏去神经对难治性动脉高血压患者办公室血压的有效性和安全性:系统回顾与元分析》。","authors":"Jose Guilherme Maia, Francinny Alves Kelly, Ocilio Ribeiro Gonçalves, Francisco Cezar Aquino de Moraes, Marcio Gonçalves de Sousa, Fernanda Marciano Consolim-Colombo","doi":"10.1007/s40292-024-00671-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Resistant arterial hypertension (RAH) is one of the main causes of increased cardiovascular risk around the world. The benefits of ultrasound renal denervation (uRDN) as a non-invasive treatment are still not fully clear.</p><p><strong>Aim: </strong> We aim to demonstrate the efficacy of uRDN in reducing office blood pressure of patients in treatment for RAH.</p><p><strong>Methods: </strong>PubMed, Embase, and Cochrane were searched for randomized trials comparing uRDN to sham or medical control groups in RAH patients undergoing renal denervation. Mean Differences (MD) with 95% confidence intervals (CIs) were calculated, and I<sup>2</sup> statistics assessed heterogeneity. Statistical significance was set at p < 0.05. Statistical analysis was performed using R software version 4.2.3.</p><p><strong>Results: </strong>It was included 5 studies with 709 patients, of which 395 (55.71%) received uRDN treatment and 314 (44.29%) in the sham group. Mean follow-up time ranged from 2 to 48 months and mean age ranged from 52.3 to 62 years. The uRDN decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP) in all measures significantly, including reductions in Office SBP (MD - 4.459 mmHg; 95% CI - 7.710 to - 1.208; p = 0.007; I<sup>2</sup> = 47%) and Office DBP (MD - 2.039 mmHg; 95% CI - 3.975 to - 0.102; p = 0.039; I<sup>2</sup> = 27%).</p><p><strong>Conclusions: </strong>This meta-analysis highlights uRDN's superiority over the sham group in controlling SBP and DBP in RAH. However, further studies are needed to fully understand the efficacy of uRDN procedure in the management of RAH.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"657-667"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Ultrasound Renal Denervation on Office Blood Pressure of Patients with Resistant Arterial Hypertension: A Systematic Review and Meta-analysis.\",\"authors\":\"Jose Guilherme Maia, Francinny Alves Kelly, Ocilio Ribeiro Gonçalves, Francisco Cezar Aquino de Moraes, Marcio Gonçalves de Sousa, Fernanda Marciano Consolim-Colombo\",\"doi\":\"10.1007/s40292-024-00671-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Resistant arterial hypertension (RAH) is one of the main causes of increased cardiovascular risk around the world. The benefits of ultrasound renal denervation (uRDN) as a non-invasive treatment are still not fully clear.</p><p><strong>Aim: </strong> We aim to demonstrate the efficacy of uRDN in reducing office blood pressure of patients in treatment for RAH.</p><p><strong>Methods: </strong>PubMed, Embase, and Cochrane were searched for randomized trials comparing uRDN to sham or medical control groups in RAH patients undergoing renal denervation. Mean Differences (MD) with 95% confidence intervals (CIs) were calculated, and I<sup>2</sup> statistics assessed heterogeneity. Statistical significance was set at p < 0.05. Statistical analysis was performed using R software version 4.2.3.</p><p><strong>Results: </strong>It was included 5 studies with 709 patients, of which 395 (55.71%) received uRDN treatment and 314 (44.29%) in the sham group. Mean follow-up time ranged from 2 to 48 months and mean age ranged from 52.3 to 62 years. The uRDN decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP) in all measures significantly, including reductions in Office SBP (MD - 4.459 mmHg; 95% CI - 7.710 to - 1.208; p = 0.007; I<sup>2</sup> = 47%) and Office DBP (MD - 2.039 mmHg; 95% CI - 3.975 to - 0.102; p = 0.039; I<sup>2</sup> = 27%).</p><p><strong>Conclusions: </strong>This meta-analysis highlights uRDN's superiority over the sham group in controlling SBP and DBP in RAH. However, further studies are needed to fully understand the efficacy of uRDN procedure in the management of RAH.</p>\",\"PeriodicalId\":12890,\"journal\":{\"name\":\"High Blood Pressure & Cardiovascular Prevention\",\"volume\":\" \",\"pages\":\"657-667\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"High Blood Pressure & Cardiovascular Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40292-024-00671-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-024-00671-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

导言:抵抗性动脉高血压(RAH)是全球心血管风险增加的主要原因之一。超声肾脏去神经支配(uRDN)作为一种非侵入性治疗方法的益处尚不完全清楚。目的:我们旨在证明uRDN在降低接受RAH治疗的患者诊室血压方面的疗效:方法:在PubMed、Embase和Cochrane中检索了对接受肾脏去神经治疗的RAH患者进行uRDN与假对照组或药物对照组比较的随机试验。计算了平均差(MD)和95%置信区间(CI),并用I2统计量评估了异质性。统计显著性以 p < 0.05 为标准。统计分析使用 4.2.3 版 R 软件进行:共有5项研究纳入了709名患者,其中395人(55.71%)接受了uRDN治疗,314人(44.29%)接受了假治疗。平均随访时间为 2 至 48 个月,平均年龄为 52.3 至 62 岁。uRDN能显著降低所有测量指标的收缩压(SBP)和舒张压(DBP),包括降低办公室SBP(MD - 4.459 mmHg; 95% CI - 7.710 to - 1.208; p = 0.007; I2 = 47%)和办公室DBP(MD - 2.039 mmHg; 95% CI - 3.975 to - 0.102; p = 0.039; I2 = 27%):这项荟萃分析强调了uRDN在控制RAH患者SBP和DBP方面优于假体组。然而,要全面了解uRDN治疗RAH的疗效,还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy and Safety of Ultrasound Renal Denervation on Office Blood Pressure of Patients with Resistant Arterial Hypertension: A Systematic Review and Meta-analysis.

Introduction: Resistant arterial hypertension (RAH) is one of the main causes of increased cardiovascular risk around the world. The benefits of ultrasound renal denervation (uRDN) as a non-invasive treatment are still not fully clear.

Aim:  We aim to demonstrate the efficacy of uRDN in reducing office blood pressure of patients in treatment for RAH.

Methods: PubMed, Embase, and Cochrane were searched for randomized trials comparing uRDN to sham or medical control groups in RAH patients undergoing renal denervation. Mean Differences (MD) with 95% confidence intervals (CIs) were calculated, and I2 statistics assessed heterogeneity. Statistical significance was set at p < 0.05. Statistical analysis was performed using R software version 4.2.3.

Results: It was included 5 studies with 709 patients, of which 395 (55.71%) received uRDN treatment and 314 (44.29%) in the sham group. Mean follow-up time ranged from 2 to 48 months and mean age ranged from 52.3 to 62 years. The uRDN decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP) in all measures significantly, including reductions in Office SBP (MD - 4.459 mmHg; 95% CI - 7.710 to - 1.208; p = 0.007; I2 = 47%) and Office DBP (MD - 2.039 mmHg; 95% CI - 3.975 to - 0.102; p = 0.039; I2 = 27%).

Conclusions: This meta-analysis highlights uRDN's superiority over the sham group in controlling SBP and DBP in RAH. However, further studies are needed to fully understand the efficacy of uRDN procedure in the management of RAH.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.70
自引率
3.30%
发文量
57
期刊介绍: High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes:   Invited ''State of the Art'' reviews.  Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信